[ Pharmaceutical Sciences Asia - ONLINE ]
Print ISSN 2586-8195 E-ISSN 2586-8470
[ Journal Abbreviation: Pharm.Sci.Asia ]
Mahidol University Journal of Pharmaceutical Sciences
  FORMER NAME   "Mahidol University Journal of Pharmaceutical Sciences" Published Since 1974


DOI: 10.29090/psa.2021.01.19.089Pharm Sci Asia 2021; 48(1), 52-60

Guideline Concordance Of Bisphosphonates Used For Osteoporosis In A University Hospital

Supalerk Anusathitwattana1, Paphon Sa-ngasoongsong2, Preecha Montakantikul1, Nantaporn Lekpittaya3, Busba Chindavijak1*

1 Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Thailand
2 Department of Orthopaedics, Faculty of Medicine Ramathibodi hospital, Mahidol University, Thailand
3 Department of Clinical Pharmacy, Faculty of Medicine Ramathibodi hospital, Mahidol University, Thailand

Bisphosphonates (BPs) are recommended as the first-line medication for osteoporosis mostly occurs in postmenopausal women and elderly men. This study was conducted to investigate (i) the percentage of prescribing BPs concordant to the Thai Osteoporosis Foundation 2010 (TOPF 2010) guideline, (ii) the cause of prescribing BPs non-concordant to the TOPF 2010 guideline, (iii) the prevalence of osteoporotic fracture, (iv) the factors related to osteoporotic fracture, and (v) the loss of medication cost determined from group of patients who received BPs non-concordant to the TOPF 2010 guideline. A nested casecontrol study was performed in all patients of Ramathibodi Hospital who consumed BPs during January and December 2012. One thousand patients were eventually recruited. Of these, 784 patients (78.4%) received BPs concordant to the TOPF 2010 guideline and 216 patients (21.6%) did not. The major cause of using BPs nonconcordant to the TOPF 2010 guideline was low bone mass without clinical risk factors (104 of 216 patients, 48.1%). Prevalence of osteoporotic fractures was 2.9%. Age (men ≥70 years and women ≥65 years) showed significant factor related to osteoporotic fracture with OR 1.0658 (95%Cl: 1.0248-1.1084; P=0.0015). Loss of medication cost in the group of patients who received BPs nonconcordant to the TOPF 2010 guidelines was 4,261,488 THB/year. In conclusion, the concordance of BPs with TOPF 2010 guideline was 3.6 times higher than the non-concordance (78.4% concordance and 21.6% non-concordance).


Bisphosphonates; Postmenopausal women; Osteoporosis; Osteoporotic fracture; Guideline concordance

Download full paper (PDF File size: 398.65 KB.)

January - February 2021

See other volume


Aims and Scope
Editorial Board
Publication Ethics
Instruction to Authors
All Volumes & Issues
Submit Online
Contact us
Faculty of Pharmacy Mahidol University
Mahidol University
Member's menu

You're now loging on with following account:
Guest (unknown)

Please Sign in or Register

    Copyright © 2017
    Faculty of Pharmacy, Mahidol University, THAILAND